ZnO is an important component in skin-protection products and wound-care medicines. However, ZnO's antibacterial activity is moderate. We developed two types of ZnO microparticles loading with phthalocyanine-type photosensitizers (ZnO/PSs) introducing the photodynamic effects. These photosensitive ZnO microparticles exhibited long-term while moderate antimicrobial effects by continuously releasing Zn ions. The antimicrobial efficacies were remarkably enhanced by triggering the photodynamic antimicrobial effects. Compared to the sole ZnO which showed non-measurable antimicrobial activity at a concentration of 10 mg/L, both ZnO/PSs demonstrated antimicrobial rates ranged 99%-99.99% against Escherichia coli, normal and drug-resistant Staphylococcus aureus. In a dorsal wound infection mouse model, treatment with ZnO/PSs significantly accelerated the wound recovery rates. ZnO/PSs promoted wound healing by a dual effect: 1) the release of Zn ions from ZnO facilitating tissue remodeling; 2) the photodynamic effect efficiently eliminates pathogens avoiding infection. Notably, ZnO/PSs inherited the high biosafety of ZnO without causing noticeable toxicity against erythrocyte and endothelial cells. This study not only provides a highly safe and efficient antimicrobial ZnO material for skin cares and wound modulations, but also proposes a strategy to functionalize ZnO materials.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.bioadv.2022.212728 | DOI Listing |
J Infect Dev Ctries
December 2024
Internal Medicine Department, Faculty of Medicine, Ain Shams University, Cairo, Egypt.
Introduction: The objective of this study was to assess the effectiveness of ivermectin and colchicine as treatment options for coronavirus disease 2019 (COVID-19).
Methodology: A three-arm randomized controlled clinical trial was conducted in the Triage Clinic of the family medicine department at Ain Shams University Hospitals on participants who had been diagnosed with moderate COVID-19. Patients aged < 18 years or > 65 years, with any co-morbidities, pregnant or lactating females, and those with mild or severe COVID-19 confirmed cases were excluded.
J Infect Dev Ctries
December 2024
Students' Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran.
Introduction: Inflammation plays a role in coronavirus disease 2019 (COVID-19) pathophysiology and anti-inflammatory drugs may help reduce the disease severity. Levamisole is an anthelmintic drug with immunomodulatory and possible antiviral effects. This study aimed to evaluate the role of levamisole in the treatment of patients with COVID-19.
View Article and Find Full Text PDFVirol J
January 2025
Medi-X Pingshan, Southern University of Science and Technology, Shenzhen, Guangdong, 518118, China.
Background: SHEN26 (ATV014) is an oral RNA-dependent RNA polymerase (RdRp) inhibitor with potential anti-SARS-CoV-2 activity. Safety, tolerability, and pharmacokinetic characteristics were verified in a Phase I study. This phase II study aimed to verify the efficacy and safety of SHEN26 in COVID-19 patients.
View Article and Find Full Text PDFBMC Plant Biol
January 2025
Department of Integrative Agriculture, College of Agriculture and Veterinary Medicine, United Arab Emirates University, P.O. Box 15551, Al Ain, Abu Dhabi, United Arab Emirates.
This study investigated the effects of non-thermal atmospheric plasma (NTAP) treatment on the growth, chemical composition, and biological activity of geranium (Pelargonium graveolens L'Herit) leaves. NTAP was applied at a frequency of 13.56 MHz, exposure time of 15 s, discharge temperature of 25 °C, and power levels (T1 = 50, T2 = 80, and T3 = 120 W).
View Article and Find Full Text PDFBMC Infect Dis
January 2025
Department of Respiratory Medicine, Faculty of Medicine, Hokkaido University, North 15 West 7, Kita-ku, Sapporo, 060-8638, Japan.
Background: Mycobacterium avium complex (MAC) is a common pathogen causing non-tuberculous mycobacterial infections, primarily affecting the lungs. Disseminated MAC disease occurs mainly in immunocompromised individuals, such as those with acquired immunodeficiency syndrome, hematological malignancies, or those positive for anti-interferon-γ antibodies. However, its occurrence in solid organ transplant recipients is uncommon.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!